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Abstract: Trans fatty acids (TFAs) are a recent focus of health problems. TFA is a definitive 
risk factor for cardiovascular diseases and the death. TF A is also possible risk factor for 
Alzheimer's disease, obesity, diabetes, fatty liver, and ovulation infertility. The relationship 
between TF A and carcinogenic risk is controversial; however, TF A is reported to increase the 
risk of breast cancer and prostate cancer. Elaidic acid (EA), a trans form of oleic acid, enhances 
cancer cell growth, invasion, and anti-apoptotic survival. In animal models, EA promotes tumor 
growth and metastasis to the lung, liver, and peritoneum. EA induces sternness in cancer 
cells through transactivation of EFGR via SRC from GPR40/120 as receptors in EA-integrated 
cholesterol rafts. Activated EGFR relays the signals to activate canonical and non-canonical wnt 
pathways and to inactivate notchl pathways. EA also increases miR-494, which inhibits cell 
differentiation through decrease of target genes. Continuous EA feeding with dosage alteration 
increased cancer cell sternness. EA diminishes the efficiency of 5-fluorouracil by increasing 
residual cancer stem cells. These findings suggest that TF A is a relevant cancer promoting 
factor. The decision to remove TF A from foods made by the FDA might have an impact on 
cancer clinics. 
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Trans fatty acid 
Unsaturated fatty acids generally have cis configurations, which are opposed to trans 
configurations 1l. Trans fatty acids (TF As) are uncommon in nature and usually generated in 
industrial processes. TF As are provided with trans configurations by hydrogenation, which 
depends mainly on oil temperature, hydrogen pressure, stirring speed, reaction time, and the 
catalyst type and concentration 1l. TF As are widely used in margarine and snack foods, and to 
shorten the frying of fast foods. 
The health problem evoked by TF As are a focus of public interest as well as basic or clinical 
research. An increase of 2% in the daily energy through TF A is associated with a 23% increase 
in cardiovascular risk of myocardial infarction and chronic heart disease death 2' 3). The totality 
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of analyses supports the proportionality of changes in TF A intake and changes in blood lipids 
(and therefore, CHD risk) and supports the use of a linear regression model to describe this 
relationship 4). 
The American Heart Association recommends limiting trans fats to <1% energy, and 
the American Dietetic Association, the Institute of Medicine, US Dietary Guidelines, and 
the National Cholesterol Education Project all recommend limiting dietary trans-fat intake 
from industrial sources as much as possible 2l. Regulations grounded on maximum limits and 
mandated labeling can lead to reductions in actual and reported TF As in food and appear to 
encourage food producers to reformulate products 5). Food and Drug Administration (FDA) 
labeling rules had allowed products containing <0.5 g trans fat per serving to claim 0 g trans 
fat 2l. June 17, 2015, the FDA issued a final determination that there is no consensus that 
industrially-produced TF As are generally recognized as safe for any use in human food. Trans 
fat must be removed from prepared foods within three years by June 2018 4). 
Cardiovascular disorder and TF A 
Monounsaturated fatty acids, on the other hand, have a positive impact on the serum lipid 
profile, lead to decreased LDL-oxidation and favorably influence the metabolism of diabetics 6). 
Concerning polyunsaturated fatty acids, it is important to increase the supply of n-3 fatty acids 
(ratio of n-6:n-3: about 5:1) as there is substantial evidence for their protective effects 6). 
As mentioned above, trans fatty acids have been identified as an important cause of 
cardiovascular disease and the resulting clinical end points such as strokes and heart attacks 7). 
Similar to saturated fatty acids, trans fatty acids increase plasma low density lipoprotein (LDL)-
cholesterol concentrations. In contrast to saturated fatty acids, trans fatty acids do not increase 
high density lipoprotein (HDL)-cholesterol concentrations 8: 9). 
TF A may also worsen insulin sensitivity, particularly among individuals predisposed to 
insulin resistance; possible effects on weight gain and diabetes incidence require further 
confirmation 3l. TFA upregulated the mRNA levels of resistin and downregulated PPARy and 
lipoprotein lipase (LPL) 10). The alteration in the mRN A levels of PP ARy and resistin could be 
associated with insulin resistance in TF A-fed rats. 
Carcinogenesis and TF A 
Literature has proved a direct connection between trans fatty acids and not only 
cardiovascular diseases but also breast cancer, nonaggressive prostate cancer, ovulatory 
infertility, Alzheimer's disease, diabetes, fatty liver, obesity and allergy 3: 11-17). However, in 
numerous experimental models and human studies, there is insufficient and inconsistent 
evidence linking specific TF A isomers to cancers of the prostate, colon and breast 18). The 
significant changes in TF A intakes between then and the end of follow-up in 1994 limit the 
reliability of this observation. There is insufficient evidence to allow any differentiation between 
the effects of TF As of animal or vegetable origin on cancer risk 19). In an animal model, 25% EA 
diet does not enhance colon carcinogenesis in F344 female rats induced by azoxymethan 20). 
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Cancer progression and EA 
Elaidic acid (EA; Cl8:1 1::. 9, trans) is a trans form of oleic acid (OA; Cl8:1 1::. 9, cis), and 
constitutes the largest quantity in dietary TF As. In a previous study, Ehrlich ascites tumors in 
EA-fed mice showed higher proliferative activity than those in OA-fed mice and this shortened 
the survival rate of mice by 45% at maximum 21). EA tends to be more incorporated into Ehrlich 
ascites tumor cells and less oxidized than OA 22). 
EA increases cell growth, invasion and anti-apoptotic survival in colorectal cancer (CRC) 
cells 23). In mouse models, EA enhances tumor growth and metastasis of CRC cells to the lung, 
liver, and peritoneum at more pronounced levels than OA treatment 23). The same amount of 
peritoneal metastasis occurred with lxl03 cells unber EA treatment as with lxl05 cells under 
OA treatment 23). These results suggest that EA might induce sternness of the CRC cells. 
Cancer stem cell and EA 
Recent studies have focused on the sternness of the cancer cells in the responsibility for 
carcinogenis and metastasis 24). Dysregulation of normal stem cells produces transformed stem 
cells, which are the tumor-initiating cells or cancer stem cells CSCs 25' 26). In the CSC model, only 
CSCs can propagate tumors at carcinogenesis and cancer metastasis 27). Activation of the signal 
pathways of wnt, hedgehog, and notch is deeply associated with cancer stem cell dysregulation 
27-31). The diversity of normal stem cells is reflected in CSCs, generating heterogeneity and 
plasticity of the progeny 32). Thus, CSCs are an essential therapeutic target, however, the 
conventional anti-cancer therapies are not effective against CSCs 33' 34). The study of substances 
affecting CSCs might provide some novel valuable information on handling CSCs. In the present 
study, the pro-tumoral effect of EA is studied with a focus on cancer stem cell modification. 
EA increases sphere formation of CRCs, which possess high sternness 23' 35). EA treatment 
induces greater expression of nucleostemin in a monolayer culture and CD133 in sphere assays 
in comparison with OA treatment 23). Spheres of EA-treated CRCs show larger size and higher 
proliferative activity than OA-treated cell spheres 23). The increase of sternness caused by EA 
provides resistance to 5-fluorouracil treatment 36). 
Receptor, intracellular signal of EA 
G-protein coupled receptors (GPRs) are known as receptors of long chain fatty acids. GPR40 
and GPR120 in particular function as receptors for unsaturated long-chain free fatty acids, such 
as OA or LA 37). Binding of EA to GPR40 and 120 is confirmed by surface protein internalization 
assay; however, knockdown of these two receptors does not abrogate completely the increased 
proliferative activity of spheres 23). EA might possess another receptor for the function. 
EA is involved into triglycerides, cholesterol esters, and phospholipids as well as other 
long chain fatty acids, such as OA, LA 38). However, EA shows low affinity to intestinal lymph 
triglyceride in comparison with OA 39). EA is incorporated into the plasma membrane as well as 
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incorporated into triglyceride 401• EA in the plasma membrane is integrated in the cholesterol 
raft, which involves EGFR and GPR40/120. The transactivation of EGFR from GPR40/120 
occurrs through Src activation 231• Crosstalk between GPCR and EGFR is reported to activate 
phospholipases C, D, and A2, which subsequently activates PKC/PKD, Raf/MEK/ERK, and 
AktlmTOR/p70S6K 411. 
EGFR signaling upregulates nucleostemin and snail, and downregulates notchl and 
E-cadherin in CT26 cells carrying wild type APC. In contrast, the signal upregulates 
nucleostemin, wnt5a and CD44, and downregulates notchl in APC null HT29 cells 231• Thus 
EA provides enhancement of proliferative stem activity and epithelial-mesenchymal transition 
phenotype. These effects are closely linked to the prominent metastatic potential of EA-treated 
cancer cells. 
microRNA and EA 421 
The expression levels of many micro-RNAs (miRNAs) are altered in EA treated CT26 
CRC cells examined by miRNA array 421• miRNA-494 is one of the increased miRNAs, whose 
function, especially in cancer, has not been elucidated. The effect of the treatment of miR-
494 inhibitor or miR-494 mimic concurrently with EA on sternness is examined by a sphere 
assay. Sphere density was increased by EA; however, a strong increase is observed with 
mimic treatment. Meanwhile, sphere density is decreased by inhibitor treatment. CD133 and 
NS increased with mimic and EA, whereas the inhibitor treatment abrogated the expression 
of CD133 and NS 421• The target genes of miR-494 contained differentiation factors for cancer 
stem cells. The expressions of PP ARy coactivator lA, PTEN, and activin A receptor lC are 
reduced by treatment with EA and the mimic, and increased by the inhibitor 421• Thus, miR-494 
expression is suggested to be promoted by EA, to maintain the sternness of cancer stem cells 
by suppressing differentiation factors 421• 
Continuous feeding of EA diet 431 
The effect of intermittent feeding restriction (IFR) is simulating human habits of feeding, 
which are quite variable both temporally and quantitatively. The effect of IFR and food 
contents on cancer are studied using a mouse model. CT26 CRC cells were inoculated into the 
back of a syngeneic BALB/c mouse. A 24-hour fast was implemented once a week for 4 weeks. 
The effect of oral intake of TF As on tumor stem cells with IFR was examined using the model. 
Mice fed with 10% EA diet (EA)+IFR, and a control diet (CD)+IFR are compared with EA 
alone or CD alone. The order from highest to lowest in terms of tumor weight and tumor MIBl 
index (cell proliferation)is: EA+IFD, CD+IFR, EA, and CD. In EA+IFR, NS-positive tumor cells 
are transiently increased on the next day of feeding restriction. After 6 weeks with 12 IFRs, 
NS-positive CT26 cells are increased in EA+ IFR in comparison with EA alone. These findings 
suggest that alteration of feeding habits might enhance cancer sternness. 
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Ruminant TF A 
Recent research has now identified an important cardioprotective role for a sub-category 
of trans fats, the ruminant trans fats 7>. TFAs contained in meat of the ruminant animals or 
vegetable oils have different features from industrial TF As 44>. However, no relationship is 
found between ruminant TF A intake levels of up to 4.2% of daily energy intake and changes 
in cardiovascular risk factors such as total-cholesterol: HDL-cholesterol and LDL-cholesterol: 
HDL-cholesterol ratios. Moreover, a multivariate regression analysis that included other dietary 
variables shows that doses of ruminant TF A did not significantly influence the changes in the 
lipid ratio 45>. 
Conjugated linoleic acid 
Conjugated linoleic acid (CLA) is composed of positional- and stereo-isomers of 
octadecadienoate (18:2), which is recognized as one of the ruminant TFAs 44>. The 
chemoprotective properties of CLA are reported in experimental cancer models and in vitro 
examinations 44' 46>. In contrast, LA has carcinogenic properties. LA, an w-6 polyunsaturated 
fatty acid, is a stereoisomer of CLA. COX-2 metabolizes LA to PGE2, which plays roles 
in carcinogenesis due to its properties of pro-inflammation, pro-proliferatation, and 
immunosuppression 47' 48>. CLA activates PP ARy as a ligand 49' 50>. PP ARy is a nuclear hormone 
receptor superfamily of ligand-activated transcription factors, which initiate transcription of 
genes associated with energy homeostasis 51>. 
CLA affects the risk of cardiovascular disease (CVD) and cancer more than industrial TF As 
52>. CLA supplementation is associated with a significant decrease in LDL cholesterol, and not 
associated significantly with decrease in HDL cholesterol, increase in total cholesterol and 
decrease in TAG 53>. Supposed adverse effects such as oxidative stress, insulin resistance, 
irritation of the intestinal tract and milk fat depression are also examined. It seems that no 
consistent result was observed even in similar studies conducted at different laboratories, this 
may be due to variations in age, gender, racial and geographical disparities, coupled with type 
and dose of CLA supplemented 54>. 
The effect of CLA was examined using gastrointestinal cancer cell lines 55). CLA inhibited cell 
growth and invasion of MKN28 and Colo320 cancer cells with an increment in apoptosis. CLA 
induced growth inhibition was recovered by knockdown of PP ARy in both cell lines. In a nude 
mouse peritoneal dissemination model, CLA treatment significantly decreases the metastatic 
foci of both cells in the peritoneal cavity and the survival rate in mice is significantly recovered 
by CLA treatment. CLA treatment provides a decrease in EGFR and TGF- a and an increase 
in Bax 55> in these cells. The anti-tumoral effect of CLA is confirmed with a syngeneic mouse 
peritoneal dissemination model of C57BL6 mice and LL2 cells 56>. 
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Conclusion 
Drawing on the above overview, numerous reports indicate that TF A is a pivotal factor 
threatening health, evoking risks for almost all of the lifestyle-related diseases. Cardiovascular 
diseases are already recognized as a disease associated with TF As. Our recent studies show 
that TF As are closely associated with cancer promotion through induction of cancer sternness. 
Now TFAs are a social problem for regulation, i.e. subject to FDA decision. At the same time, 
the importance of elucidating the bioactive cancer-related functions of fatty acids is suggested. 
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